Trial reportUrology2019
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
Trial report in Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Patterns of disease detection using [European journal of nuclear medicine and molecular imaging · 2021Trial
- Observational Management for Patients with Biochemical Recurrence Following Radical Prostatectomy, in the Absence of Detectable Disease on Restaging PSMA PET/CT Imaging.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Patterns of failure withCanadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Observational
- Radiotheranostics in advanced prostate cancer: Current and future directions.Prostate cancer and prostatic diseases · 2024Review
- The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective.Cancers · 2023Review
- Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.Biomedicines · 2022Review
- Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET.Cancers · 2022Review
- Changes in Management AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2022Review
- Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives.Cancers · 2022Review
- The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment.Seminars in nuclear medicine · 2022Review
- Molecular Imaging, How Close to Clinical Precision Medicine in Lung, Brain, Prostate and Breast Cancers.Molecular imaging and biology · 2022Review
- Pattern of Prostate Cancer Recurrence Assessed byJournal of clinical medicine · 2021Article
- [European journal of nuclear medicine and molecular imaging · 2021Article
- M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting.BJUI compass · 2021Article
- Article
- Clinical value of negativeEuropean journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify locations of recurrence after radical prostatectomy (RP) with prostate-specific antigen (PSA) <2 by Gallium-68 prostate-specific membrane antigen (PSMA)-11 Positron Emission Tomography (PET) imaging, and to determine whether standard nodal radiation fields would cover the location of prostate cancer recurrence. MATERIALS AND
methodsWe performed a retrospective review of patients with PSMA-PET imaging for biochemical recurrence following RP with PSA ≤2.0 ng/mL and assessed if the recurrent disease was within standard radiation target volumes. We compared patient and clinical variables between men with recurrences covered by standard salvage radiation fields and those with recurrences outside of standard fields.
resultsWe identified 125 patients for study inclusion. The median PSA at imaging was 0.40 ng/mL (interquartile range 0.28-0.63). PSMA-avid disease was found in 66 patients (53%). Of these, 25 patients (38%) had PSMA-avid lesions found outside of the pelvis, 33 (50%) had lesions confined to the pelvic lymph nodes and prostate bed, and 8 (12%) men had PSMA-avid recurrence only in the prostate bed. Salvage radiation including standard Intensity Modulated Radiation Therapy (IMRT) pelvic nodal volumes would not cover PSMA-avid nodal disease in 38 men (30%). PSA at the time of imaging was statistically associated with having PSMA-avid disease outside of standard nodal fields (P <.01).
conclusionThe 68Ga-PSMA-11 PET detects disease in a majority of patients with PSA ≤2.0 following RP. Nearly one-third of men had PSMA-avid disease that would be missed by standard radiation fields. This imaging modality may dramatically impact the design and use of post-RP salvage radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.